Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary efficacy endpoint. READ MORE Source: Marketwatch
Research published in Nature Medicine reveals key information around one of the most distressing side effects of diabetes. This study offers vital new insights into how abnormal glucose metabolism produces heightened pain in diabetics. Further research is being undertaken to develop new treatments. READ MORE Source: Science Daily
Researchers from Yale and the West Haven Veterans Affairs Medical Center have published findings in the Journal of Neuroscience describing how changes in the structure of dendritic spines are associated with pain in laboratory rats with diabetes. Dendritic spines are microscopic projections on the receiving branches of nerve calls. This study “reveals that these dendritic …
Yale Team Discovers Unexpected Source of Diabetic Neuropathic Pain Read More »
Janssen Pharmaceuticals, Inc. presented results at the 31st Annual Scientific Meeting of the American Pain Society suggesting these extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy. “Painful DPN is a common and burdensome complication of diabetes, and controlling pain in …
Phase 3 Data Show NUCYNTA® ER Extended-Release Tablets Provide Pain Relief Management Read More »
Later this year, NeuroMetrix hopes to launch a new device to treat the effects of diabetic peripheral neuropathy (DPN). They are working with the FDA to get their new product through the regulatory process. They currently have a nerve conduction testing product that is used as a diagnostic tool for DPN. READ MORE Source: NeuroMetrix
The US FDA has agreed to resume clinical trials with anti-nerve growth (NGF) drugs despite cases of side effects stating the risk-benefit profile indicated a role for their ongoing development. The drugs are being developed for the treatment of a variety of chronic painful conditions, including diabetic peripheral neuropathy. READ MORE Source: Medscape
The results of a 13-week study by Avanir Pharmaceuticals, published in the journal Pain Medicine, show efficacy and safety of AVP-923 for treatment of diabetic neuropathic pain. Currently also in study for multiple sclerosis, the combination of Dextromethorphan and Quinidine (AVP-923) showed its effectiveness in treating diabetic neuropathic pain, particularly a reduction in leg pain. READ …
Publication of Phase III Study Shows Positive Results for Diabetic Neuropathic Pain Read More »
A new study from University of Michigan researchers found that the most efficient testing is not always done for peripheral neuropathy – especially diabetes related neuropathy. Led by Dr. Brian Callaghan, Assistant Professor of Neurology, the team found that many tests can be given but physicians are highly variable in approach. There is a lot …
Nutri-Med Logic Corp has taken the results of a recent published study, in the European Journal of Nutrition to report on the benefits of R-Alpha Lipoic for Diabetes. This article reports on the study and expands on the benefits of this nutrient. Â READ MORE Source: PRWeb
Diabetic neuropathy may be an added risk for hypothermia because neuropathy can impair the body’s ability to control body temperature. Neuropathy also poses a risk for frostbite. There are several winter complications to be aware of if you suffer with diabetic neuroapathy…. Â READ MORE Source:Â Diabetes Take It On!
